Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

At least four biotechs announced venture rounds this week, including rare mineralization disorders play Inozyme and three companies backed by Asian investors.

Inozyme Pharma Inc. (Boston, Mass.) raised $67 million in a series A2 round that will enable the company to develop enzyme replacement therapy INZ-701 to treat severe disorders of calcification associated with deficiencies in ENPP1 including generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets type 2 (ARHR2)...